title: HeLiVa platform: integrated heart-liver-vascular systems for drug testing in human health and disease.
abstract: Our project team is developing an integrated microphysiological platform with functionally connected vascular, liver and cardiac microtissues derived from a single line of human pluripotent stem cells. The platform enables functional representation of human physiology in conjunction with real-time biological readouts (via imaging and homologous reporters for all three cell phenotypes) and compatibility with high-throughput/high-content analysis. In this paper, we summarize progress made over the first year of the grant.
authors.forename: Gordana
authors.initials: G
authors.lastname: Vunjak-Novakovic
authors.forename: Sangeeta
authors.initials: S
authors.lastname: Bhatia
authors.forename: Christopher
authors.initials: C
authors.lastname: Chen
authors.forename: Karen
authors.initials: K
authors.lastname: Hirschi
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use / Q000633:toxicity; D002454:Cell Differentiation; D004558:Electric Stimulation; D042783:Endothelial Cells / Q000166:cytology; D006526:Hepatitis C / Q000188:drug therapy; D022781:Hepatocytes / Q000166:cytology* / Q000187:drug effects; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000166:cytology*; D046210:Microfluidic Analytical Techniques / Q000295:instrumentation / Q000379:methods; D032383:Myocytes, Cardiac / Q000166:cytology* / Q000502:physiology
chemical_list: D000998:Antiviral Agents